PuSH - Publication Server of Helmholtz Zentrum München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Gastaldelli, A.* ; Stefan, N. ; Häring, H.-U.

Liver-targeting drugs and their effect on blood glucose and hepatic lipids.

Diabetologia 64, 1461-1479 (2021)
Publ. Version/Full Text DOI PMC
Open Access Hybrid
Creative Commons Lizenzvertrag
The global epidemic of non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) and the high prevalence among individuals with type 2 diabetes has attracted the attention of clinicians specialising in liver disorders. Many drugs are in the pipeline for the treatment of NAFLD/NASH, and several glucose-lowering drugs are now being tested specifically for the treatment of liver disease. Among these are nuclear hormone receptor agonists (e.g. peroxisome proliferator-activated receptor agonists, farnesoid X receptor agonists and liver X receptor agonists), fibroblast growth factor-19 and -21, single, dual or triple incretins, sodium-glucose cotransporter inhibitors, drugs that modulate lipid or other metabolic pathways (e.g. inhibitors of fatty acid synthase, diacylglycerol acyltransferase-1, acetyl-CoA carboxylase and 11β-hydroxysteroid dehydrogenase type-1) or drugs that target the mitochondrial pyruvate carrier. We have reviewed the metabolic effects of these drugs in relation to improvement of diabetic hyperglycaemia and fatty liver disease, as well as peripheral metabolism and insulin resistance.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
10.122
2.542
4
10
Tags
Annotations
Special Publikation
Hide on homepage

Edit extra information
Edit own tags
Private
Edit own annotation
Private
Hide on publication lists
on hompage
Mark as special
publikation
Publication type Article: Journal article
Document type Review
Keywords Farnesoid X Receptor Agonists ; Fibrosis ; Hepatokines ; Incretins ; Insulin Resistance ; Non-alcoholic Fatty Liver Disease ; Non-alcoholic Steatohepatitis ; Peroxisome Proliferator-activated Receptor (ppar) Agonists ; Review ; Sglt2 Inhibitors; Type-2 Diabetes-mellitus; Improves Insulin Sensitivity; Cotransporter 2 Inhibitor; Glucagon-like Peptide-1; X-receptor Agonist; Placebo-controlled Trial; Tyrosine-phosphatase 1b; Fatty Liver; Nonalcoholic Steatohepatitis; Double-blind
Language english
Publication Year 2021
HGF-reported in Year 2021
ISSN (print) / ISBN 0012-186X
e-ISSN 1432-0428
Journal Diabetologia
Quellenangaben Volume: 64, Issue: 7, Pages: 1461-1479 Article Number: , Supplement: ,
Publisher Springer
Publishing Place Berlin ; Heidelberg [u.a.]
Reviewing status Peer reviewed
Institute(s) Institute of Diabetes Research and Metabolic Diseases (IDM)
POF-Topic(s) 90000 - German Center for Diabetes Research
Research field(s) Helmholtz Diabetes Center
PSP Element(s) G-502400-001
Grants Consiglio Nazionale delle Ricerche
DOI 10.1007/s00125-021-05442-2
WOS ID WOS:000641662300001
Scopus ID 85104996942
PubMed ID 33877366
Erfassungsdatum 2021-05-28
[➜Report correction]